New obesity drug targets body fat distribution in clinical trial
NCT ID NCT07169942
Summary
This study is testing whether an experimental medication called aleniglipron can change body composition in people with obesity. 71 adults with a body mass index of 30 or higher will receive either the drug or a placebo for 40 weeks. Researchers will measure changes in body fat, muscle mass, and weight using specialized scans to see if the drug affects where fat is stored in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY, OVERWEIGHT, OR CHRONIC WEIGHT MANAGEMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Phoenix, Arizona, 85020, United States
-
Research Site
Chicago, Illinois, 60602, United States
-
Research Site
Richfield, Minnesota, 55423, United States
-
Research Site
City of Saint Peters, Missouri, 63303, United States
-
Research Site
Rochester, New York, 14609, United States
-
Research Site
Wilmington, North Carolina, 28401, United States
-
Research Site
Norman, Oklahoma, 73069, United States
-
Research Site
Moncks Corner, South Carolina, 29461, United States
-
Research Site
North Charleston, South Carolina, 29405, United States
-
Research Site
Austin, Texas, 78704, United States
-
Research Site
San Antonio, Texas, 78240, United States
Conditions
Explore the condition pages connected to this study.